跳至主要内容
临床试验/NCT02915406
NCT02915406No Longer Available不适用

cliniMACs HUD for T Cell Depletion

University of Miami1 个研究点 分布在 1 个国家开始时间: 2016年9月27日最近更新:
适应症

试验速览

阶段
不适用
状态
No Longer Available
试验地点
1

研究概览

简要总结

This protocol is designed to enable access to related or unrelated CD34 cells manufactured using the CliniMACS (Miltenyi) under the HUD designation for patients needing T cell depleted allogeneic grafts for hematopoietic stem cell transplant (HSCT). This will include patients with inherited immunodeficiency disorders as well as patients with malignancies, bone marrow failure, and other rare diseases amenable to HSCT. Finally, patients with poor graft function and Graft Versus Host Disease(GVHD) after a previous HSCT may require a boost of T-cell depleted donor Peripheral Blood Stem Cell (PBSCs) or bone marrow cells that are CD34 selected using the CliniMACS device ENROLLMENT BY INVITATION ONLY

研究设计

研究类型
Expanded Access

入排标准

年龄范围
— 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • severe combined immune deficiency need for stem cell boost

排除标准

  • 未提供

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gary Kleiner

Associate Professor of Pediatrics

University of Miami

研究点 (1)

Loading locations...

相似试验